The clinical benefit of undertaking cancer research includes access to the most novel and innovative cancer therapies. It has led to new drug treatments, a greater understanding of how to prevent cancer, new ways of delivering treatments and new surgical techniques. Cancer clinical trials are critical to advances in the understanding and treatment of cancer and to ensure patients have the opportunity to access world-class cancer treatments.
There is evidence to suggest that clinical research activity is a driver for high-quality cancer care with better outcomes for patients who are treated in research-intensive hospitals (National Institute for Health Research, 2014).
We have highlighted three of our current trials below:
TROPION-Breast02 is recruiting patients with previously untreated triple negative breast cancer (TNBC) that has spread (metastatic) or TNBC that has come back and cannot be removed. This international AstraZeneca Phase III study is assessing whether a new treatment, datopotamab deruxtecan (Dato-DXd), is better than current treatments. TNBC affects 1 in 5 women with breast cancer and is more common in women <40 and black women. It is the most aggressive type of breast cancer and cannot be treated with hormonal or targeted therapies. The outcome for patients with metastatic TNBC is usually worse than other types of breast cancer, with overall survival generally less than two years and five-year survival around 12%. Current treatment options may be poorly tolerated by patients and reduce quality of life. Dato-DXd is an antibody-drug conjugate, a treatment that can target breast cancer cells and deliver a drug that stops the cells growing. Warwick Hospital is offering the promising new treatment to patients across The Midlands.
Myeloma XV (RADAR) is recruiting patients newly diagnosed with Multiple Myeloma (MM) who are able to have a stem cell transplant. MM, also known as Myeloma, is a cancer that affects the bone marrow, spongy tissue found inside some bones that produces blood cells. Over 5,500 patients are diagnosed with MM each year in the UK. MM is an incurable relapsing-remitting cancer, meaning there are periods where the disease is active (relapsing) and requires treating, followed by periods where treatment may not be required (remitting). Significant progress has been made in developing new lines of treatment over the past 15 years. Newly diagnosed patients now survive on average 5-6 years, with 37% of men and 28% of women surviving 10 years. Currently all MM patients are given the same treatment, this UK-based Phase III study is investigating the personalisation of MM care. Some patients will have genetic markers that suggest their cancer will be more difficult to treat. These higher-risk patients, along with those whose cancer has not responded well to initial treatment, are offered more intensive therapy to extend the remitting period, while lower risk patients can receive reduced treatment with the aim of reducing side effects.
Poetic-A is recruiting postmenopausal women diagnosed with operable early-stage hormone-sensitive breast cancer. Hormone-sensitive breast cancer, for example ER positive and HER2 negative, is made up of cells stimulated by oestrogen. Although postmenopausal women do not produce oestrogen from their ovaries, they do still make a small amount by turning other hormones into oestrogen. Women can be given endocrine (anti-hormone) therapy (ET) to keep oestrogen levels low and prevent the cancer from growing.
However, some women are at higher risk of becoming resistant to these treatments. Poetic-A is a phase III multicentre trial that assesses whether a new drug, abemaciclib, can be given to make treatment more effective than giving ET alone. This will aim to personalise care by looking at biological markers of risk, such as Ki67, to target treatment for women who are less responsive or resistant to ET and are therefore at higher risk of breast cancer coming back.
We are also recruiting to the following trials: COSMOS (Smouldering Myeloma), Cutaneous Tumour (Keratoacanthoma), Mithridate (Polycythemia vera), Nerlyfe (early-stage HR+/HER- breast cancer being treated with Neratinib), Rampart (Renal Cell Carcinoma), Rudy (AML), Stampede (Metastatic/Advancing Prostate Cancer), TransRampart (Renal Cell Carcinoma), UKGPCS (Prostate Cancer) and UKAITPR (Idiopathic Thrombocytopenic Purpura). For more information visit Be Part of Research or contact us directly.Oncology and Haematology Trials